drugset
drugset / Trial / NCT03895996

Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes

NCT03895996 ↗

Phase 1/2 Completed 25 enrolled Avotres Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a double-blind, randomized , placebo-controlled study to evaluate the safety and tolerability of AVT001, and to assess AVT001 as a potential treatment for type 1 diabetes (T1D). The trial will involve approximately 24 new-onset T1D subjects.

Timeline

Start
2019-06-20
Primary completion
2022-05-17
Completion
2023-12-19

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject AVT001 Cell therapy — Intravenous

Indications

type 1 diabetes mellitus